Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today reported its consolidated half-year accounts as of June 30, 2015 and provided an update on the key operational and clinical milestones achieved during the first six months of the year. The first half year of 2015 has been extremely active for Onxeo.
The Board of Directors of Ipsen, chaired by Marc de Garidel, met on 30 July 2015 to approve the financial statements for the first half 2015, published today. *As of 30 June 2014, net closing cash included? 80 m withdrawn from the syndicated credit facility. Commenting on the first half 2015 performance, Marc de Garidel, Chairman and Chief Execut
Deal Type: Equity Offerings Deal Sub Type: Private Placement Deal Country: China Deal Status: Announced Deal Value: 0.0000 USD. Jiangsu Sihuan Bioengineering Co., Ltd., a Beijing- based biopharmaceutical company, has announced a private placement of shares of its common stock, to raise gross proceeds of approximately CNY3, 600 million. Index- Drug
"The first half year of 2015 has been extremely active for Onxeo. In parallel, Onxeo has been particularly active focusing on elevated scientific exchange, with an increased visibility at several key medical congresses devoted to oncology, including two posters presented at the American Society of Clinical Oncology Annual Meeting. We strongly belie
Teva Pharmaceutical Industries Ltd. today announced that it has entered into commitment letters relating to its pending acquisition of Allergan s generic pharmaceuticals business with Bank of America Merrill Lynch, Barclays Bank PLC, BNP Paribas, Citi, Credit Suisse, HSBC, Mizuho Bank, Morgan Stanley Senior Funding, Inc., RBC Capital Markets and
Allergan's ANDA product is a generic version of United Therapeutics Corporation's Tyvaso , which is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability. United Therapeutics filed suit against Allergan on July 22, 2015 in the U.S. District Court for the District of New Jersey seeking to prevent Allergan from.
BRUSSELS- The European Commission Wednesday said it has approved the acquisition of Perrigo of Ireland by Mylan of the Netherlands, under the EU Merger Regulation. Perrigo is specialized in selling over-the-counter drugs, available without prescription in pharmacies. In the limited instances where both Mylan and Perrigo sell pharmaceutical products
The first half year of 2015 has been extremely active for Onxeo. In parallel, Onxeo has been particularly active focusing on elevated scientific exchange, with an increased visibility at several key medical congresses devoted to oncology, including two posters presented at the American Society of Clinical Oncology Annual Meeting. We strongly bel
REDONDO BEACH, CA/ ACCESSWIRE/ July 30, 2015/ With the global population surging to 7.3 billion people, there is a clear need for more food in the future. Regulators in the U.S. Food and Drug Administration have taken steps to curtail drug usage in animal feed for growth promotion, a move meant to try and curb the breeding of antibiotic-resistance
German pharmaceutical giant Bayer has posted a surprising jump in net profit for the second quarter, lifted by strong currency effects and gains in its health care, specialty plastics and agricultural chemicals sectors. Bayer on Wednesday logged a 21 percent on-the-year rise in net profit in the second quarter of 2015. The gains brought the Leverku
The Drugs Controller General of India hopes to answer this. dna had first reported about the rampant internet pharmacy racket and its modus operandi, where prescription drugs were being illegally exported from India- based suppliers and courier services. State FDA had investigated Snapdeal, Flipkart and Amazon and served them show-cause notices, as
Active Pharmaceutical Ingredients Market:- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014- 2020 Albany, NY 07/29/2015 The recent patent expiry of several blockbuster drugs has presented specialized active pharmaceutical ingredients manufacturers with ample opportunities for expansion all over the world. FDA defines AP
Naloxone nasal spray is expected to be the first FDA- approved intranasal naloxone product indicated to treat opioid overdose in the United States. "As the rate of opioid overdoses and their profound impact on communities nationwide continues to rise, naloxone nasal spray may help make every life-saving second count by potentially allowing anyone-
July 29 Marin County officials launched a new front in the war on prescription drug abuse Tuesday, saying pharmaceutical firms should pay for the safe disposal of old pills and medications. A spokeswoman for the California Retailers Association pledged cooperation. The board agreed with Supervisor Katie Rice, who called the measure a model of col
Mylan NV said Wednesday that it received European regulatory approval to move forward with its proposed buyout of Perrigo Co., which has resisted repeated overtures. In April, the generic drugmaker raised its offer for Perrigo to $232.23, or about $34.1 billion, in cash and stock. But Dublin- based Perrigo, which makes over-the-counter medicines
In case you missed it: The FDA has just issued a warning on various prescription and non-prescription drugs that Americans ingest by the boatload. Here's a blurb from the FDA website:. "FDA is strengthening an existing warning in prescription drug labels and over-the-counter Drug Facts labels to indicate that nonsteroidal anti-inflammatory drugs c
The report comes from a Centers for Disease Control and Prevention survey, which monitored sexual activity and contraceptive use among about 2,000 US teens aged 15 to 19 from 2011 to 2013.. In 2013, the Food and Drug Administration approved the emergency contraceptive Plan B One-Step for use without a prescription or age restrictions. Typically cos
OPKO Health, Inc. today announced that the U.S. Food and Drug Administration has accepted for review OPKO s New Drug Application for calcifediol modified-release capsules. Kevin J. Martin, Director of the Division of Nephrology at Saint Louis University School of Medicine. If approved, Rayaldee will provide a new therapeutic option for contro
Pfizer Inc. reported financial results for second-quarter 2015 and announced increases to the midpoints of its 2015 financial guidance ranges for reported revenues and reported and adjusted diluted EPS. The Innovative Products business is composed of two operating segments: the Global Innovative Pharmaceutical segment and the Global Vaccines,...
July 28 "The acquisition of the generic division of Allergan is a game changer. It puts Teva Pharmaceutical Industries Ltd. in a position where it can once again change the rules of the generic game, "Teva president and CEO Erez Vigodman said today in a talk with" Globes, "after the company announced its acquisition of Allergan's generic division
Allergan plc today announced that it has entered into a definitive agreement under which Teva Pharmaceutical Industries Ltd. will acquire Allergan's global generic pharmaceuticals business for $40.5 billion. Allergan will receive $33.75 billion in cash and $6.75 billion in Teva stock. In addition, Allergan retains 50 percent of Teva's future econ
The Dutch drugmaker Mylan, which had resisted Teva's advances for three months, is pressing ahead with its offer for Irish drug and ingredients maker Perrigo. Perrigo has turned down Mylan's offer. If they can't work it out, Perrigo might find other suitors as the competitive generic drug industry keeps consolidating.
Document Number: "Docket ID: DOD -2012- HA-0049". EFFECTIVE DATE: This final rule is effective August 26, 2015. George E. Jones, Jr., Chief, Pharmacy Operations Division, Defense Health Agency, telephone 703-681-2890..
WASHINGTON, July 27 The Department of Defense published the following rule in the Federal Register:. Civilian Health and Medical Program of the Uniformed Services/ TRICARE: TRICARE Pharmacy Benefits Program. A Rule by the Defense Department on 07/27/2015.
By a News Reporter-Staff News Editor at Pharma Business Week The U.S. Food and Drug Administration announced that it is strengthening an existing label warning that non-aspirin nonsteroidal anti-inflammatory drugs increase the chance of heart attack or stroke. The FDA reached its decision to strengthen NSAID warning labels following a comprehensi